Skip to main content

Advertisement

Table 1 Risk factors and histopathologic characteristics of HNC cases (N = 109)1 by baseline HPV-16 E6/E7 status

From: Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study

Characteristics HPV-16 E62 Adjusted OR5 HPV-16 E73 Adjusted OR5 HPV-16 E6 and/or E74 Adjusted OR5
  Positive n (%) Negative
n (%)
  Positive n (%) Negative
n (%)
  Positive n (%) Negative
n (%)
 
Gender          
   Male 15 (68.2) 52 (59.8) 3.0 (0.9-9.4) 15 (75.0) 52 (58.4) 3.4 (1.01-11.5) 17 (65.4) 50 (60.2) 1.9 (0.7-5.2)
   Female 7 (31.8) 35 (40.2) 1.0 5 (25.0) 37 (41.6) 1.0 9 (34.6) 33 (39.8) 1.0
Age Group          
   ≤ 55 years 14 (63.6) 30 (34.5) 2.7 (0.96-7.7) 12 (60.0) 32 (36.0) 2.7 (0.9-7.6) 15 (57.7) 29 (34.9) 2.5 (0.97-6.6)
   > 55 years 8 (36.4) 57 (65.5) 1.0 8 (40.0) 57 (64.0) 1.0 11 (42.3) 54 (65.1) 1.0
Number of Partners          
   0-2 7 (33.3) 35 (43.7) 1.0 6 (33.3) 36 (43.4) 1.0 9 (37.5) 33 (42.9) 1.0
   3-9 5 (23.8) 23 (28.8) 1.4 (0.4-5.7) 4 (22.2) 24 (28.9) 1.3 (0.3-5.6) 5 (20.8) 23 (29.9) 1.0 (0.3-3.6)
   ≥ 10 9 (42.9) 22 (27.5) 6.9 (1.5-33.2) 8 (44.4) 23 (27.7) 5.6 (1.2-26.5) 10 (41.7) 21 (27.3) 4.5 (1.1-18.6)
Pack years          
   Never 6 (27.3) 23 (26.4) 1.0 4 (20.0) 25 (28.1) 1.0 6 (23.1) 23 (27.7) 1.0
   ≤ 30 12 (54.5) 14 (16.1) 4.0 (1.1-14.1) 10 (50.0) 16 (18.0) 4.6 (1.2-18.3) 12 (46.2) 14 (16.9) 4.1 (1.2-14.3)
   > 30 4 (18.2) 50 (57.5) 0.4 (0.1-1.8) 6 (30.0) 48 (53.9) 1.1 (0.2-4.7) 8 (30.8) 46 (55.4) 1.0 (0.3-3.5)
Drinks per Week          
   Never 6 (27.3) 28 (32.2) 1.0 5 (25.0) 29 (32.6) 1.0 7 (26.9) 27 (32.5) 1.0
   ≤ 21 10 (45.5) 34 (39.1) 2.0 (0.6-6.6) 9 (45.0) 35 (39.3) 1.8 (0.5-6.1) 12 (46.2) 32 (38.6) 1.7 (0.6-5.2)
   > 21 6 (27.3) 25 (28.7) 3.7 (0.8-18.1) 6 (30.0) 25 (28.1) 2.5 (0.6-11.3) 7 (26.9) 24 (28.9) 2.0 (0.5-7.8)
Tumor Site          
   Oropharynx 20 (90.9) 7 (8.1) 51.9 (2.7-1007.0)6 16 (80.0) 11 (12.4) 4.1 (0.5-32.6) 20 (76.9) 7 (8.4) 7.9 (1.04-60.8)
   Oral Cavity 2 (9.1) 71 (81.6) 0.7 (0.03-14.9)6 2 (10.0) 71 (79.8) 0.1 (0.01-0.7)6 4 (15.4) 69 (83.1) 0.2 (0.02-1.2)6
   Larynx\hypopharynx 0 (0.0) 9 (10.3) 1.0 2 (10.0) 7 (7.9) 1.0 2 (7.7) 7 (8.4) 1.0
Oropharynx vs. Oral Cavity    19.7 (5.3-73.9)7    10.1 (2.9-35.8)7    24.2 (1.5-384.0)7
Stage          
   I/II 2 (9.1) 38 (43.7) 1.0 1 (5.0) 39 (43.8) 1.0 3 (11.5) 37 (44.6) 1.0
   III/IV 20 (90.9) 49 (56.3) 23.7 (4.2-133.6) 19 (95.0) 50 (56.2) 26.2 (3.1-221.8) 23 (88.5) 46 (55.4) 11.3 (2.8-45.8)
Tumor Size          
   T0-T2 18 (81.8) 45 (52.9) 1.0 13 (65.0) 50 (57.5) 1.0 19 (73.1) 44 (54.3) 1.0
   T3-T4 4 (18.2) 40 (47.1) 0.3 (0.1-1.04) 7 (35.0) 37 (42.5) 0.9 (0.3-2.6) 7 (26.9) 37 (45.7) 0.5 (0.2-1.4)
Grade          
   Poor/Undifferentiated 11 (50.0) 14 (16.1) 5.5 (1.8-17.1) 9 (45.0) 16 (18.0) 3.7 (1.3-11.1) 12 (46.2) 13 (15.7) 4.8 (1.7-13.7)
   Well/Moderate 11 (50.0) 73 (83.9) 1.0 11 (55.0) 73 (82.0) 1.0 14 (53.8) 70 (84.3) 1.0
Nodal Involvement          
   Yes 20 (90.9) 31 (35.6) 37.3 (6.8-204.3) 17 (85.0) 34 (38.2) 11.3 (2.8-45.1) 21 (80.8) 30 (36.1) 9.4 (2.9-30.0)
   No 2 (9.1) 56 (64.4) 1.0 3 (15.0) 55 (61.8) 1.0 5 (19.2) 53 (63.9) 1.0
HPV DNA          
   High-Risk 20 (90.9) 10 (11.5) 22.0 (6.2-77.2)7 16 (80.0) 14 (15.7) 27.8 (7.2-107.8) 21 (80.8) 9 (10.8) 60.1 (13.9-259.4)
Type 16 19 (90.5) 9 (10.5) 25.1 (6.6,-95.2)7 16 (80.0) 12 (13.9) 32.5 (8.2-129.6) 20 (80.0) 8 (9.0) 58.0 (13.7-246.3)
Type 33 1 (0.4) 1 (1.0) NE 0 (0.0) 2 (1.8) NE 1 (0.8) 1 (1.8) NE
   Negative 2 (9.1) 77 (88.5) 1.0 4 (20.0) 75 (84.3) 1.0 5 (19.2) 74 (89.2) 1.0
  1. 1Number of patients; percentages (%) based on available data; 2Cases seropositive for HPV-16 E6 compared to cases seronegative for HPV-16 E6; 3Cases seropositive for HPV-16 E7 compared to cases seronegative for HPV-16 E7; 4Cases positive for E6 and/or E7 compared to cases negative for E6 and E7; 5Adjusted for continuous age, continuous pack years, and continuous drinks per week; 6Unadjusted logit estimator of OR; 7Logit estimator of OR and 95% CI., adjusted for categorical age, categorical pack years, and categorical drinks per week.